Research programme: DNA interference therapies - Sierra Oncology
Alternative Names: PNT 100; PNT 200; PNT 300; PNT 400; PNT 500; PNT 600Latest Information Update: 08 Jul 2022
At a glance
- Originator ProNAi Therapeutics
- Developer Sierra Oncology
- Class Oligonucleotides
- Mechanism of Action BIRC5 protein modulators; DNA modulators; KRAS protein modulators; Proto-oncogene protein c-bcl-2 modulators; STAT3 transcription factor modulators; Transforming growth factor alpha modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 01 Jul 2022 Sierra Oncology has been acquired by GlaxoSmithKline
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 09 Jan 2017 ProNAi Therapeutics is now called Sierra Oncology